Treatment strategies in follicular lymphomas: Current status and future perspectives

Journal of Clinical Oncology

Volumn 23, Issue 26, 2005, Pages 6394-6399

  Hiddemann, Wolfgang ^a   Buske, Christian ^a   Dreyling, Martin ^a   Weigert, Oliver ^a   Lenz, Georg ^a   Forstpointner, Roswitha ^a   Nickenig, Christina ^a   Unterhalt, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RADIOISOTOPE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; VINDESTINE; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ADJUVANT THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE DURATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FOLLICULAR LYMPHOMA; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECOND CANCER; WHOLE BODY RADIATION; ADULT; AGE; AGED; AUTOTRANSPLANTATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 27244434957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.019     Document Type: Review

References (37)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: The Non-Hodgkin's Lymphoma Classification Project. Blood 89: 3909-3918, 1997
2. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311: 1471-1475, 1984
3. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
4. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94-3325-3333, 1999
5. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
6. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up. J Clin Oncol 18:527-536, 2000
7. Van Besien K, Loberiza FR, Bajorunaite R, et al: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003
8. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21: 3918-3927, 2003
9. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674, 2004
10. Deconinck E, Foussard C, Milpied N, et al: High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS. Blood 2005, in press
11. Sebban C, Belanger C, Brousse N, et al: Comparison of CHVP + Interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden Follicular Lymphoma: Results of the randomized GELF94 trial (G.E.L.A. Study Group). Blood 102:l04a, 2003 (abstr 354)
12. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000
13. Howe R, Micallef IN, Inwards DJ, et al: Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 32:317-324, 2003
14. Lenz G, Dreyling M, Schiegnitz E, et al: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22:4926-4933, 2004
15. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
16. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003
17. Shan D, Ledbetter JA, Press OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673-683, 2000
18. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997
19. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
20. Feuring-Buske M, Kneba M, Unterhalt M, et al: IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79:493-500, 2000
21. Hainsworth JD, Litchy S, Burris HA, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
22. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
23. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with Rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103:4416-4423, 2004
24. Hainswoth J, Sitchy S, Greco FA: Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin's lymphoma (NHU responding to single-agent rituximab: A randomized trial of the Minnie Pearl Cancer Research Network. Blood 102:69a, 2003 (abstr 231)
25. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular Non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9 year follow-up. J Clin Oncol 22:4711-4716, 2004
26. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantel cell Lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 104:3064-3071, 2004
27. Hiddemann W, Dreyling MH, Forstpointner R, et al: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood (in press)
28. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
29. Herold M, Pasold R, Srock S, et al: Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHU and mantle-cell-lymphoma (MCL). Blood 104:169a, 2004 (abstr 584)
30. Salles G, Foussard C, Nicolas M, et al: Rituximab added to alFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 104:49a, 2004 (abstr 160)
31. Hochster HS, Weller E, Ryan T, et al: Results of E 1496: A phase III trial of CVP with or without maintenance Rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 23:556, 2004 (abstr 6502)
32. Solal Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
33. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine (131)I Tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
34. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
35. 131Itositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005
36. Gopal AK, Gooley TA, Maloney DG, et al: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: A multivariable cohort analysis. Blood 102:2351-2357, 2003
37. Press OW, Unger JM, Braziel RM, et al: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 102:1606-1612, 2003